Archive · 9 Jun 2025
Glenmark to Launch Brukinsa for Blood Cancer Treatment in India
Glenmark Pharmaceuticals is set to launch Brukinsa, a cancer medicine called zanubrutinib, in India after receiving approval.
This oral drug is a BTK inhibitor and treats five types of blood cancers.
Developed by BeiGene (now BeOne Medicines), it is designed with fewer side effects and has shown promising results in trials.
The drug is already approved in over 70 countries and offers flexible dosing.
Glenmark expects Brukinsa to be a new line of treatment with fewer heart-related complications.
Glenmark Pharmaceuticals will launch Brukinsa (zanubrutinib) in India.
Brukinsa is a BTK inhibitor for treating five B-cell malignancies.
The drug was developed by BeiGene (now BeOne Medicines).
DCGI has approved Brukinsa for use in India.
Brukinsa has shown fewer cardiac issues compared to other drugs in trials.
- Who
- Glenmark Pharmaceuticals
- What
- Will launch Brukinsa (zanubrutinib), a cancer treatment.
- When
- In the coming months
- Where
- India
- Why
- To provide a new treatment option for five B-cell malignancies.
- Company Launching
- Glenmark Pharmaceuticals
- Drug Name
- Brukinsa (zanubrutinib)
- Approval Granted By
- DCGI
- Targets
- Five B-cell malignancies
- Developed By
- BeiGene (now BeOne Medicines)
- Drug Type
- Oral, small-molecule BTK inhibitor
